Navigation Links
Vivakor Signs Business Development Agreement With Baker Consulting
Date:12/16/2009

CORALVILLE, Iowa, Dec. 16 /PRNewswire-FirstCall/ -- Vivakor, Inc. (OTC Bulletin Board: VIVK) has signed a Business Development agreement with Baker Consulting out of Walnut Creek, California and its affiliate group, Kyouko Group, Inc. out of South Florida. Baker Consulting has been retained by Vivakor to assist with business development, financing and assisting the company with its recently reported acquisition strategy. Specifically, Baker Consulting is exploring potential acquisition targets for Vivakor in the areas of ophthalmological devices and treatment solution companies as well as other targets aligned with Vivakor's existing divisions. In addition to vetting and presenting specific opportunities, Baker Consulting is continuing to present financing opportunities for these transactions as well as for Vivakor's existing operations.

About Vivakor, Inc.

Vivakor is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds, that extend or improve life. More information can be found about Vivakor at www.vivakor.com.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's products, markets and business strategies. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.


    Contact:
    Vivakor Investor Relations
    c/o IME Advisors
    (888) 648-8485

SOURCE Vivakor, Inc.


'/>"/>
SOURCE Vivakor, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Vivakor Divisions Continue to Demonstrate Independent Growth
2. Vivakor Announces Launch of VivaThermic Website and Highlights Distribution & Sales of Its VivaThermic Products in Japan Through Veritas Corporation
3. Vivakor Announces New Acquisition Strategy
4. Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects
5. AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts
6. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
7. Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up
8. MedQuist Signs Agreement Extending Use of Real-Time Speech Recognition Engine to Wide Range of Medical Specialties
9. US Trauma Fixation Device Market Not Seeing Signs of Slowdown
10. WorldHeart Signs Agreements for Next-Generation Minimally Invasive Blood Pump
11. CareFusion Signs Multi-Year Technology Licensing Agreement for Masimo Rainbow SET(R) Pulse CO-Oximetry(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Australien, 24. Februar 2017 ITL ... Unternehmen des Gesundheitsbereiches, ist erfreut, für das zum ... dem entsprechenden Vorjahreszeitraum exzellente Ergebnisse vorlegen zu können. ... Aktualisierung zum Wachstum" finden Sie hier . ... Gewinn nach Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)... 23, 2017  This report analyzes the worldwide markets ... Products: Intermediates, Analytical, and Others. The ... Pharmaceuticals, and Agrochemicals. The report provides separate comprehensive analytics ... Europe , and Rest of World. Annual ... through 2022. Also, a six-year historic analysis is provided ...
(Date:2/24/2017)... 2017 Medivir AB (Nasdaq Stockholm: ... new Board of Directors that will be submitted to ... comprises representatives of the company,s three largest shareholders at ... have accepted a seat on the Nomination Committee, and ... 2016-2017 Nomination Committee was as follows:  ...
Breaking Medicine Technology:
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... provides business development, education, networking and recognition opportunities as well as advocacy for ... Works in Holmdel, NJ on February 23. The Council's Innovation Forecast event ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... and hearing disabilities, it is so critically important that we all are aware ... That is why Mediaplanet is proud to announce the launch of its newest ...
(Date:2/24/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... Yisrayl makes an astounding statement when he says that the entire Bible was written ... the current times so plainly that anyone should be able to see the time ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... into the Senior International Elite division on February 12th. Ms. Esparza qualified ... at the elite qualifier competition held in Las Vegas, Nevada. Frida is one ...
(Date:2/23/2017)... Miami, FL (PRWEB) , ... February 23, 2017 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – will return to the La Gorce Country Club in Miami Beach ...
Breaking Medicine News(10 mins):